undamentalytics Newsletter
Sign in

Ispecimen Inc. key statistics and ratios

In fiscal 2025, Ispecimen Inc. had an operating margin of -465.4%, debt equal to 0.0% of equity and a current ratio of 1.12. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Gross margin56.2%52.9%54.3%51.9%45.0%11.2%−98.0%
Operating margin−29.4%−53.2%−97.9%−112.5%−137.0%−465.4%<−999%
Net margin−56.8%−80.5%−98.5%−111.8%−134.5%−543.7%<−999%
Free-cash-flow margin−3.5%−95.8%−58.0%−58.7%−89.3%−219.9%<−999%
Return on equity——−40.9%−73.9%−191.5%——
Return on assets−74.9%−42.7%−34.0%−54.9%−99.3%−111.1%−135.0%
Asset turnover1.320.530.340.490.740.200.06
Current ratio0.1613.154.601.360.621.120.82
Debt to equity—11.7%20.9%0.0%0.0%0.0%0.0%
Interest cover (operating income ÷ interest)n/mn/mn/mn/mn/mn/m—
R&D as % of revenue3.9%7.9%14.2%16.3%16.1%——
Capital spending as % of revenue0.0%0.0%2.1%0.2%0.3%0.0%0.0%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

1 of 3 checks passed · June 30, 2026
What it owns · $7m
Short-term assets $4mLonger-term assets $3m
What it owes, and who funded it · $7m
Short-term liabilities $5mLonger-term liabilities $0mShareholders' equity $2m
  • Short-term assets cover short-term liabilities $4m of assets due within a year against $5m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $4m short-term assets against $179,721 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$9m against $1,949 of interest.

From Ispecimen Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

26 /100

Weak moat

How hard Ispecimen's competitive advantage looks for rivals to wear away, judged from 6 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -25.4% of total assets over 5 years.

  • Pricing power 9 / 20

    Gross margin has been a median 49.8%, moving by 55.3 percentage points (standard deviation) across 6 years.

  • Durability 10 / 20

    Operating margin has been a median -104.8%; its worst year was -2020.0%.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (32 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: ISPC vs YDESISPC vs QSIACON vs ISPC

More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies

Figures from Ispecimen Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Ispecimen Inc.